July 2012

Dear Colleagues: 

Many of you are hopefully currently enjoying a great summer season. Despite the vacation season for many, the IASLC activities are moving forward. 

The JTO Chief Editor search has met its dead-line and several strong candidates are now being evaluated. We hope to complete interviews within the next few months. 

The search for IASLC CEO is still open (see below). 

This week IASLC will have the Latin American Lung Cancer Meeting in Rio de Janeiro, Brazil, which has already many registrants. On-site registration is still possible (see below). 

The program for the 2012 Chicago Thoracic Multidisciplinary Symposium has been finalized and many very exciting abstracts have been received for presentation (see below). 

The Asian Pacific Lung Cancer Conference (APLCC) in Fukuoka, Japan, November 26-28, 2012, has already received many very good abstracts for presentation. 

The IASLC Chinese Fellowship Program received many applications and will now be evaluated by the Fellowship Committee. 

Finally, the new IASLC multidisciplinary adenocarcinoma webinar has been launched and can be found at

The IASLC Board and Headquarters wish all a healthy and happy summer season. 

Fred R. Hirsch, MD, PhD 

Editor, IASLC Newsletter 

IASLC Chief Executive Officer 

The International Association for the Study of Lung Cancer (IASLC) has opened its search for candidates for Chief Executive Officer (CEO). The CEO serves as the leader of the IASLC, representing the organization in all internal and external activities. The CEO reports to the President and the Board of Directors and is responsible for ensuring that the IASLC activities set by the Board are carried out. The CEO is responsible for ensuring that the IASLC reaches the mission, goals and strategic plan set forth by the Board of Directors. 

The CEO is responsible for providing strategic leadership for the IASLC by working with the Board of Directors and the management team to establish long-range goals, strategies, plans and policies in support of the IASLC mission to: 

  • Promote the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies; 
  • Disseminate information about lung cancer and other thoracic malignancies to the members of the Association, to the medical community at large, and to the public; and, 
  • Use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.  

The IASLC Executive offices are located in Aurora, Colo. It is expected that the CEO will spend at least 75 percent effort in his/her role of CEO of the IASLC. With Board approval, the CEO may spend the remainder of his/her working week in other academic/clinical positions related to thoracic oncology. This may include a part time appointment in an academic or other institution approved by the Board. The CEO must be in regular contact with the Executive Office, but may live and have an academic appointment at a location outside of Colorado and the USA with Board approval. 

Principal Duties 

1. Works effectively with the Board to support the IASLC’s mission, goals and strategic plan. 

2. Works with the Board to develop, monitor and revise the strategic plan. 

3. Works with the Board and staff to secure funding and sponsorship for all IASLC activities. 

4. Provides leadership and management to ensure that the mission, vision and core values of the IASLC are developed, communicated and implemented. 

5. Responsible for leading the IASLC to achieve and surpass membership, educational, research and financial goals and objectives.  

6. Spearheads the development, communication and implementation of effective growth strategies and processes. 

7. Collaborates with the management team to develop and implement plans for the operational infrastructure of systems, processes and personnel designed to accommodate the growth objectives of the IASLC. 

8. Motivates and leads a high-performance management team, attracts, recruits and retains required staff and provides appropriate mentoring for their success. 

9. Represents the IASLC with members, donors and other partners. 

10. Establishes credibility throughout the IASLC and with the Board of Directors as an effective developer of solutions to management, mission and other challenges. 

11. Fosters a success-oriented, accountable environment within the organization. 

12. Oversees the IASLC activities of the COO/CFO and other staff. 

Position Requirements 

The CEO is expected to be a physician member of the IASLC and who has a career focus on thoracic oncology. More than 10 years of experience in oncology activities, leadership activities and administrative activities are required. 

To perform the job successfully, an individual should demonstrate the following competencies to perform the essential functions of this position. 

  • Leadership— proven success in leading, inspiring, motivating, and managing other professionals; personal creativity and strategic vision, coupled with an ability to listen to others and learn from their best ideas; 
  • Management skills— demonstrated ability to inspire trust, organize people into effective teams and motivate them to work well together; includes staff in planning, decision-making, facilitating and process improvement; makes self available to staff; provides regular performance feedback; and develops subordinates’ skills and encourages growth; 
  • Delegation—delegates work assignments and gives authority to work independently; sets expectations and monitors delegated activities; 
  • Demonstrated management acumen— proven record in maintaining or increasing organizational viability and effectiveness, and comfort in dealing with the budgeting process and management of staff and financial resources; 
  • Demonstrated fundraising ability, particularly with individuals, endowments and foundations and a willingness to try new ideas in fundraising; 
  • Judgment—displays a willingness to make decisions, exhibits sound and accurate judgment, and makes timely decisions; 
  • Communications—communicates clearly and persuasively, both orally and in writing, in positive or negative situations; demonstrates group presentation skills and conducts productive meetings; 
  • Analytical—synthesizes complex and diverse information; 
  • Problem solving—identifies and resolves problems in a timely manner and gathers and analyzes information skillfully; 
  • Quality management—looks for ways to improve and promote quality and demonstrates accuracy and thoroughness; 
  • Planning/organizing—prioritizes and plans work activities, uses time efficiently and develops realistic action plans. 

Minimum Qualifications 

1. Must be a physician member in good standing in the IASLC. 

2. Demonstrated effectiveness with interpersonal and public relations essential. 

3. High level of attention to planning, execution and details. 

4. Must be experienced with international meetings of all sizes. 

5. Must possess the ability to balance the needs and desires of multiple constituencies and cultures. 

6. Must exhibit great diplomacy in guiding members and leaders from varying cultures and languages, and with diverse agendas and skill levels, to agree on the most logical and beneficial actions that will ensure the success of IASLC and the achievement of its mission. 

7. Leadership experience in nonprofit or philanthropic organizations such as service on the executive, board or committee member, preferably having served in several elected or appointed offices at international level. 

8. Requires proficiency in English and experience with presentations to audiences of varying sizes and make-up. 

9. Should be seen as a recognized leader within the field of lung cancer/thoracic malignancies research and treatment. 

Inquiries and submissions should be sent to: 

IASLC Search Committee 

Send documents electronically to: 

More information can be found on the IASLC website, 

Submission should be delivered by Sept. 15, 2012 and include a letter of interest, a one- to two-page vision statement, a curriculum vitae and a plan of how to effectively engage and manage IASLC staff in Denver. 

Please remember to pay the IASLC membership fee 2012 - $200 

Registering online is fast and easy! Visit for more information. 

IASLC members will be sent renewal reminders and invoices. Register now so there will no interruption to your JTO subscription, and to receive discounts on 2012 meeting fees. Please contact the Membership Department if you need any assistance paying your dues: 

5th Latin American Conference on Lung Cancer 

For more information or 

2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, September 6-8, 2012 

5th APLCC ITMIG IASLC Conference, November 26-28, 2012 

IASLC Web-based Education Programs 


In 2011, the Journal for Thoracic Oncology published the “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,” issued by a multidisciplinary team of lung cancer specialists. To better understand the general implications of this new classification, and the issues affecting specific specialties, please join us for this On-Demand Webinar Series. 

Module 1 - Introducing The New IASLC/ATS/ERS Lung Adenocarcinoma Classification

Module 2 - Implications of the New IASLC/ATS/ERS Classification; Module 3 - Highlights for the Pathologist; Module 4 - Highlights for the Radiologist; Module 5 - Case Studies for the Practicing Clinician 

Please go to for more details 

Women and Lung Cancer - CME-certified Audio-guided Web course 

The International Association for the Study of Lung Cancer (IASLC) has partnered with joint sponsors Penn State College of Medicine and Rockpointe to bring a CME-certified webcourse to oncologists caring for patients with lung cancer. 

Joan H. Schiller, MD chairs the program with faculty Edward Garon, MD and Heather Wakelee, MD. Program Description: The treatment of NSCLC has been revolutionized in the past decade, with an increased understanding of the need for individualization of therapy. Histologic and molecular features of NSCLC predict response to targeted agents and certain chemotherapies. Gender should also play a role in treatment, as lung cancer biology, natural history, and treatment outcomes vary between men and women. 

This educational initiative was designed to help community oncologists integrate personalization of therapy into the treatment of NSCLC patients. The goal is to enhance knowledge, clinical competence, and performance of clinicians with respect to diagnosis, staging, and treatment options – thereby leading to improved patient outcomes. The activity is supported by an educational grant from Lilly, USA and Genentech BioOncology. 

Click here to view activity:

IASLC Staging Manual: 

The IASLC Staging Manual and Handbook in Thoracic Oncologic has now surpassed 35,000 copies sold worldwide. In addition, the Staging Posters and Reference Cards continue to be popular reference aids of the 7th edition staging system for practitioners and tumor boards. IASLC members can continue to order these publications and products at special member pricing (; contact for further information). 

In addition, translations of these publications have been completed or are in process in multiple languages: Chinese, Italian, Japanese, Polish, and Turkish. Discussions about future translations in Spanish, Arabic, and Russian are ongoing. 

The new IASLC Staging Manual has been published in different formats. Several years of work from the IASLC Staging Committee and particularly the chair Dr. Peter Goldstraw, has resulted in a formal staging manual. The book and the “pocket-cards” can be ordered at




iPhone/iPad Staging Atlas






Dr. D. Ross Camidge, MD, PhD was awarded the Fifth Annual Addario Foundation Keynote Lecture at the 13th International Lung Cancer Congress in Huntington Beach, CA, USA. Dr. Camidge is Associate Professor at the University of Colorado and Director for the Clinical Thoracic Program. The award recognizes among other things particularly his significant contribution to the clinical development of ALK- inhibitors. 








National Lung Cancer Partnership 

Young Investigator Research Grant Competition 

The National Lung Cancer Partnership is pleased to announce our 8th annual research grant competition. This year, multiple 2-year $100,000 awards are available to clinical and basic science fellows and junior faculty. 

The purpose of this grant program is to drive research forward that will increase understanding of lung cancer, while ensuring that young investigators have the resources needed for them to succeed as lung cancer researchers. Basic, translational, or clinical proposals are eligible for funding. Research that will lead to significant improvement in lung cancer prevention, detection, diagnosis, screening, treatment, and symptom management is sought. 

At the time of application, an applicant must hold a doctoral degree (MD, PhD, DO, DrPH, or equivalent), and be a post-doctoral fellow or be in the first 5 years of their first faculty appointment at a not-for-profit institution in the United States or Canada. Complete application eligibility and instructions are available on the National Lung Cancer Partnership’s website:

Special Opportunity for Investigators in North Carolina: Through supplementary support from the North Carolina Lung Cancer Partnership, one additional grant may be awarded to an investigator in North Carolina with a meritorious score. 

The application deadline is August 20, 2012. Awards will be announced on or before December 31, 2012. 

Upcoming IASLC Workshops/Meetings 2012- 2015 

5th Latin American Lung Cancer Conference 

July 25-27, 2012 

Location: Rio de Janeiro, Brazil 

More information: 

Australian Lung Cancer Conference 

Adelaide, South Australia 

August 23-25, 2012 

More information: 

Chicago Multidisciplinary Symposium in Thoracic Oncology 

September 6-8, 2012 

Location: Hotel Marriott, Chicago, Illinois, U.S.A. 

More information: 

3rd International thoracic Oncology Congress 

Dresden, Germany 

September 13-15, 2012 


5th Asia Pacific Lung Cancer Conference 

November 26-28, 2012 Location: Hilton Sea Hawk, Fukuoka, Japan 

More information: 


15th World Conference on Lung Cancer 

October 27-31, 2013 

Location: Sydney, Australia 

More information: 


16th World Conference on Lung Cancer 

September 4-8, 2015 

Location: Denver, Colorado, USA 

More information: